New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:02 EDTXNCRXencor initiates Phase 1 study of XmAb7195 for asthma
Xencor announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb7195, a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and other atopic disease. The Phase 1 trial will evaluate safety, pharmacokinetics and immunogenicity of a single ascending dose of XmAb7195 in a total of 64 subjects.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
08:49 EDTXNCRUpdate: Xencor 7.5M share Secondary priced at $14.25
Subscribe for More Information
06:24 EDTXNCRXencor 5.5M share Secondary priced at $14.25
The deal size was increased to 7.5M shares from 5.5M shares. Leerink acted as lead book running manager for the offering.
February 23, 2015
19:44 EDTXNCRXencor to participate in a conference call with Leerink
Subscribe for More Information
16:08 EDTXNCRXencor files to sell 5.5M shares of common stock
Subscribe for More Information
February 19, 2015
16:18 EDTXNCRXencor sees sufficient cash to fund R&D through 2016
Subscribe for More Information
16:18 EDTXNCRXencor reports Q4 revenue $5.7M, consensus $2.22M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use